Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574924 | 0.86 | MAOB (0.45) | MAOASLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL1945934 | 0.86 | SLC6A2 (0.50) | HTR2CHTR2BMAPK1SLC6A2SLC6A4 | |
| SCHEMBL11779811 | 0.83 | MAPK1 (0.47) | MAPK1GAAL3MBTL1MAOAALDH1A1 | |
| SCHEMBL1945287 | 0.83 | SLC6A2 (0.44) | HTR2CHTR2BMAPK1GAAL3MBTL1 | |
| SCHEMBL1946852 | 0.82 | HTR3A (0.44) | HTR2CHTR2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1948166 | 0.80 | ADRB1 (0.48) | HTR2CMAPK1GAAL3MBTL1MAOA | |
| SCHEMBL11434944 | 0.79 | ADRB1 (0.47) | HTR2CHTR2BMAPK1GAAL3MBTL1 | |
| SCHEMBL1944636 | 0.79 | HTR2C (0.52) | HTR2CHTR2BMAPK1GAAALDH1A1 | |
| SCHEMBL7366527 | 0.77 | L3MBTL1 (0.63) | HTR2CHTR2BGAAL3MBTL1MAOA | |
| SCHEMBL164537 | 0.77 | SLC6A2 (0.59) | HTR2CHTR2BSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507215-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| WO-2011067219-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | claimed |
| EP-2507215-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011067219-A1 | DIPHENYL AZEPINE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | SCHOENFELD RYAN CRAIG | 2011-06-09 | — | — | US | disclosed |
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | SCHOENFELD RYAN CRAIG | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136787-A1 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF | PTGDR2, PTGDR, TBXA2R | HTR2C 146/4885HTR2B 220/4885MAPK1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.